This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Anthrax is not a typical travel risk. Avoid contact with sick or dead animals in endemic agricultural regions. Do not purchase unprocessed animal hides or wool. Pre-exposure vaccination is only for high-risk occupational groups.
Serious bacterial disease caused by Bacillus anthracis spores, occurring as cutaneous, inhalation, or gastrointestinal forms.
Anthrax is a serious infectious disease caused by Bacillus anthracis, a spore-forming bacterium found in soil. It occurs in three main clinical forms: cutaneous (skin), inhalation (lung), and gastrointestinal. Vaccination is available for high-risk groups.
Anthrax is primarily a disease of herbivorous animals (cattle, sheep, goats) that can be transmitted to humans through contact with infected animals or contaminated animal products. The bacterium forms highly resilient spores that can survive in the environment for decades.\n\nHuman cases are relatively rare and occur mainly in agricultural and industrial settings in endemic areas. Cutaneous anthrax accounts for about 95% of human cases. Anthrax is classified as a Category A bioterrorism agent due to the potential weaponization of spores.
Most common signs and symptoms
Symptoms depend on the form of infection.\n\nCutaneous (95% of cases): Painless papule that progresses to a vesicle, then to a characteristic black eschar (scab) with surrounding edema. Fever, malaise, and regional lymph node swelling.\n\nInhalation: Initial flu-like phase (fever, malaise, nonproductive cough) followed by abrupt deterioration with severe breathing difficulty, chest pain, and shock.\n\nGastrointestinal: Nausea, vomiting, fever progressing to severe abdominal pain, bloody diarrhea, and fluid accumulation in the abdomen.
Knowing the symptoms is the first step to a quick response.
Cutaneous: incubation period 1–12 days; lesion evolves over 7–10 days and heals in 2–6 weeks with treatment. Inhalation: incubation 1–60 days (typically 1–5 days); initial prodrome lasting 2–5 days followed by rapid fulminant phase with respiratory failure. Gastrointestinal: incubation 1–7 days with potential for rapid progression.
How this disease is identified
Diagnosis is based on clinical suspicion, exposure history, and characteristic findings such as the black eschar in cutaneous anthrax. Confirmed by laboratory culture of blood, lesion swabs, or other specimens. Rapid molecular testing (PCR) and antigen detection are available. Any suspected case must be reported to public health authorities immediately.
Available treatment methods
All forms require antibiotic therapy prescribed by a physician. Treatment is most effective when started early. Cutaneous anthrax (uncomplicated) is treated with oral antibiotics for 7–10 days. Systemic and inhalation anthrax require combination intravenous antibiotics for extended duration. Antitoxin therapy is available for inhalation anthrax. Post-exposure prophylaxis with antibiotics may be given after confirmed exposure. Always seek immediate medical care if anthrax is suspected.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Preparation is the best protection.
Statistics and geographic data
Anthrax occurs worldwide but is most common in agricultural regions of Central and South America, sub-Saharan Africa, Central and South Asia, and southern and eastern Europe. Human cases are relatively rare globally. Occupational exposure among farmers, veterinarians, and wool sorters remains the primary risk factor. Sporadic outbreaks occur after contact with infected livestock or contaminated animal products.
Who is most at risk
Potential complications
Cutaneous anthrax may lead to secondary infection or sepsis if untreated. Inhalation anthrax frequently causes hemorrhagic inflammation of the chest cavity, fluid accumulation around the lungs, meningitis, and multiorgan failure. Gastrointestinal anthrax can result in intestinal perforation, massive hemorrhage, and septic shock. All systemic forms carry high mortality risk without prompt antibiotic treatment.
Expected outcomes and recovery
Prognosis varies greatly by clinical form. Cutaneous anthrax has less than 1% fatality with appropriate treatment. Inhalation anthrax carries approximately 45% fatality even with treatment and over 85% without. Gastrointestinal anthrax fatality ranges from 25% to 60%. Early diagnosis and prompt antibiotic therapy are critical for survival in all systemic forms.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.